Scarica l'app Stockscreener
41.98
5.16%
2.06
Precedente Chiudi:
$39.92
Aprire:
$39.68
Volume 24 ore:
488.97K
Relative Volume:
1.06
Capitalizzazione di mercato:
$1.20B
Reddito:
-
Utile/perdita netta:
$-69.47M
Rapporto P/E:
-7.50
EPS:
-5.5973
Flusso di cassa netto:
$-73.92M
1 W Prestazione:
+8.67%
1M Prestazione:
+37.73%
6M Prestazione:
+83.56%
1 anno Prestazione:
+75.80%
Intervallo 1D:
$39.59
$42.08
Intervallo di 1 settimana:
$38.37
$42.08
Portata 52W:
$16.54
$42.08
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Nome
Lenz Therapeutics Inc
Settore
Industria
Telefono
858-925-7000
Indirizzo
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Confronta LENZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
41.98 | 1.14B | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2025-03-18 | Iniziato | TD Cowen | Buy |
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-04-10 | Iniziato | Citigroup | Buy |
| 2024-03-27 | Iniziato | Piper Sandler | Overweight |
| 2023-02-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-01-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-14 | Iniziato | BTIG Research | Buy |
| 2022-03-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Iniziato | Morgan Stanley | Overweight |
| 2021-07-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie
Backtesting results for LENZ Therapeutics Inc. trading strategiesJuly 2025 Price Swings & Verified Stock Trade Ideas - Newser
Real time social sentiment graph for LENZ Therapeutics Inc.July 2025 Levels & Proven Capital Preservation Tips - Newser
Can LENZ Therapeutics Inc. reach resistance levels soonPortfolio Return Report & Free Safe Entry Trade Signal Reports - خودرو بانک
Lenz Therapeutics stock hits 52-week high at 41.71 USD By Investing.com - Investing.com Canada
Earnings visualization tools for LENZ Therapeutics Inc.July 2025 Action & Weekly Setup with High ROI Potential - Newser
Is LENZ Therapeutics Inc. stock heavily shortedWeekly Stock Summary & AI Enhanced Trade Execution Alerts - خودرو بانک
Institutional scanner results for LENZ Therapeutics Inc.2025 AllTime Highs & High Accuracy Swing Trade Signals - Newser
Will LENZ Therapeutics Inc. stock go up soonLong Setup & Free Growth Oriented Trading Recommendations - Newser
Is LENZ Therapeutics Inc. exposed to currency risksPortfolio Gains Summary & Daily Stock Trend Watchlist - خودرو بانک
Lenz Therapeutics stock hits 52-week high at 41.71 USD - Investing.com
LENZ Therapeutics Inc. stock volume spike explained2025 AllTime Highs & High Conviction Trade Alerts - Newser
How much upside does LENZ Therapeutics Inc. haveExit Point & Real-Time Stock Movement Alerts - خودرو بانک
Multi factor analysis applied to LENZ Therapeutics Inc.IPO Watch & Real-Time Chart Pattern Alerts - Newser
Investment Review: Will LENZ Therapeutics Inc. outperform during market ralliesJuly 2025 Analyst Calls & Weekly High Conviction Ideas - خودرو بانک
How to manage a losing position in LENZ Therapeutics Inc.Take Profit & Real-Time Chart Breakout Alerts - Newser
Does LENZ Therapeutics Inc. outperform in volatile marketsJuly 2025 Highlights & Entry and Exit Point Strategies - خودرو بانک
Tick level data insight on LENZ Therapeutics Inc. volatilityShort Setup & Daily Risk Controlled Trade Plans - Newser
What’s the beta of LENZ Therapeutics Inc. stockEarnings Risk Summary & Detailed Earnings Play Strategies - 더경남뉴스
What the charts say about LENZ Therapeutics Inc. todayJuly 2025 Price Swings & Reliable Breakout Stock Forecasts - Newser
Can volume confirm reversal in LENZ Therapeutics Inc.2025 Short Interest & Risk Adjusted Swing Trade Ideas - Newser
Lenz Therapeutics shares fall 1.17% premarket after presenting at Citi's Biopharma Back to School Conference. - AInvest
Analyzing LENZ Therapeutics Inc. with multi timeframe chartsJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - Newser
Will LENZ Therapeutics Inc. price bounce be sustainableJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - Newser
Key metrics from LENZ Therapeutics Inc.’s quarterly data2025 Investor Takeaways & Technical Buy Zone Confirmation - Newser
What momentum shifts mean for LENZ Therapeutics Inc.July 2025 Pullbacks & Daily Stock Trend Watchlist - Newser
Trend analysis for LENZ Therapeutics Inc. this weekJuly 2025 Institutional & Technical Buy Zone Confirmation - Newser
What MACD signals say about LENZ Therapeutics Inc.July 2025 Weekly Recap & Reliable Intraday Trade Plans - Newser
Should you hold or exit LENZ Therapeutics Inc. nowJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
LENZ Therapeutics: A Case Study in Strategic Execution and Market Readiness - AInvest
Transcript : LENZ Therapeutics, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 09 - MarketScreener
Can swing trading help recover from LENZ Therapeutics Inc. lossesM&A Rumor & Safe Entry Zone Identification - Newser
Will LENZ Therapeutics Inc. rebound enough to break evenJuly 2025 Short Interest & AI Based Buy and Sell Signals - Newser
Relative strength of LENZ Therapeutics Inc. in sector analysisWeekly Gains Summary & High Win Rate Trade Alerts - Newser
Analyzing LENZ Therapeutics Inc. with risk reward ratio chartsPortfolio Growth Summary & Community Supported Trade Ideas - Newser
Will LENZ Therapeutics Inc. stock recover after recent dropIndex Update & Free Growth Oriented Trading Recommendations - Newser
Will LENZ Therapeutics Inc. outperform during market rallies2025 Volatility Report & Weekly Watchlist for Consistent Profits - خودرو بانک
Can LENZ Therapeutics Inc. expand its profit marginsJobs Report & Fast Momentum Stock Entry Tips - خودرو بانک
Block Trades: Will LENZ Therapeutics Inc. benefit from government policyWeekly Trade Analysis & Real-Time Price Movement Reports - خودرو بانک
Pullback Watch: Is LENZ Therapeutics Inc. gaining market shareMarket Rally & Technical Confirmation Trade Alerts - خودرو بانک
Why LENZ Therapeutics Inc. is moving todayWeekly Investment Report & Verified Stock Trade Ideas - Newser
What’s the profit margin of LENZ Therapeutics Inc.Quarterly Profit Review & Breakout Confirmation Trade Signals - خودرو بانک
Real time breakdown of LENZ Therapeutics Inc. stock performanceTrade Analysis Report & Real-Time Volume Surge Alerts - Newser
Lenz Therapeutics Inc Azioni (LENZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lenz Therapeutics Inc Azioni (LENZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Aug 26 '25 |
Sale |
39.01 |
47,443 |
1,850,891 |
1,274,197 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 22 '25 |
Sale |
40.15 |
26,161 |
1,050,392 |
1,374,059 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 25 '25 |
Sale |
39.54 |
25,818 |
1,020,888 |
924,175 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 26 '25 |
Sale |
39.01 |
23,368 |
911,655 |
900,807 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 22 '25 |
Sale |
40.15 |
12,885 |
517,356 |
949,993 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 15 '25 |
Sale |
39.50 |
145,051 |
5,729,514 |
1,430,848 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 15 '25 |
Sale |
39.50 |
69,949 |
2,762,986 |
977,963 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 18 '25 |
Sale |
38.56 |
30,628 |
1,181,049 |
1,400,220 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 18 '25 |
Sale |
38.56 |
15,085 |
581,694 |
962,878 |
| Versant Venture Capital VI, L. | 10% Owner |
Jul 10 '25 |
Sale |
34.00 |
191,376 |
6,506,784 |
1,575,899 |
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):